Prospective Multicenter Registry of Hybrid Coronary Artery Revascularization Combined With Surgical Bypass and Percutaneous Coronary Intervention Using Everolimus Eluting Metallic Stents

Inclusion Criteria: * Patients with stable angina, unstable angina, or non-ST elevation myocardial infarction. * Patients with multivessel coronary artery disease including significant stenotic lesion\* in the right coronary artery and also including left main stem disease. * Patients who will be referred for CABG. * Patients with significant stenotic lesion in the right coronary artery amenable to PCI. * Patients who can take DAPT medications. * Patients who provided written informed consent. \* Significant stenotic lesion means a condition where fractional flow reserve (FFR) is lower than 0.80 or visually confirmed stenosis is at least 75%. Exclusion Criteria: * • Patients with ST elevation myocardial infarction occurring within 24 hours before enrollment. * Patients who previously underwent CABG. * Patients who are at high risk of receiving CABG. * Patients who need simultaneous surgery such as valve surgery other than CABG. * Patients with a life expectancy of 1 year or shorter due to co-morbidities. * Patients with a history of cerebral infarction within the last 6 months. * Patients with congestive cardiac failure of NYHA 3 or higher. * Patients with unstable hemodynamics at enrollment. * Patients with right coronary artery disease that is chronic total occlusion and difficult to treat with PCI (J-CTO score of ≥ 23). * Patients receiving long-term dialysis. * Patients who are allergic to antiplatelet agent. * Patients who are critically allergic to contrast media. * Patients who are allergic to any DES component.